Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application

Clin Nucl Med. 2016 Aug;41(8):e386-7. doi: 10.1097/RLU.0000000000001251.

Abstract

Prostate cancer is the second most common primary tumor affecting men worldwide. Among them, 10-20% develop castration resistant prostate cancer (CRPC). Ga-PSMA-PET/CT is an important theranostic agent for the evaluation of CRPC to assess the feasibility of treatment with Lu-PSMA-617 which is a novel therapeutic agent. Interestingly, in certain cases, we have observed non-PSMA-avid lesions despite raised sPSA levels. In this regard, we present a case of cocktail therapy applied using Lu-PSMA-617 and Lu-EDTMP therapy in a 38-year-old male CRPC patient with both soft tissue and extensive skeletal metastases.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Dipeptides / administration & dosage
  • Dipeptides / therapeutic use*
  • Edetic Acid / analogs & derivatives
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Heterocyclic Compounds, 1-Ring / administration & dosage
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Male
  • Oligopeptides
  • Organometallic Compounds / therapeutic use*
  • Organophosphorus Compounds / therapeutic use*
  • Positron Emission Tomography Computed Tomography*
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / therapeutic use*

Substances

  • Dipeptides
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Heterocyclic Compounds, 1-Ring
  • Oligopeptides
  • Organometallic Compounds
  • Organophosphorus Compounds
  • PSMA-617
  • Radiopharmaceuticals
  • gallium 68 PSMA-11
  • lutetium ethylenediaminetetramethylene phosphonic acid
  • Edetic Acid
  • Prostate-Specific Antigen